Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eusa Pharma acquires Cytogen
Under the terms of the acquisition agreement, Cytogen shareholders will receive $0.62 per share, valuing the company at $22.6 million. To meet the consideration, Eusa has raised over
Under the terms of the acquisition agreement, Cytogen shareholders will receive $0.62 per share, valuing the company at $22.6 million. To meet the consideration, Eusa has raised over
Under the terms of the collaboration, Cytopia has out-licensed specific proprietary technology to Cancer Therapeutics for an undisclosed kinase enzyme target with potential for treating metastatic cancers. Under
Results from Lithe trial showed that a greater proportion of patients treated with Actemra in combination with a commonly used rheumatoid arthritis (RA) drug called methotrexate (MTX) benefited
This latest testing profile measures the oxidative products of tetrahydrobiopterin (BH4). Neopterin and biopterin are by-products of the redox reactions involving tetrahydrobiopterin (BH4). From a simple overnight urine
ALO-01 (Embeda (morphine sulfate extended-release with sequestered naltrexone hydrochloride) is an investigational pharmacologic abuse-deterrent, extended-release opioid that Alpharma is developing for the treatment of moderate to severe chronic
In this study, Relora significantly reduced short-term anxiety compared to the placebo group. The subjects reported that they have suffered from anxiety and they typically eat more in
US WorldMeds’s improved reconstitution product is expected to meet all current FDA approved release specifications. The company plans to file a submission in 2008 to obtain FDA approval
COL-003 contains oxycodone as its active ingredient and utilizes the company’s DETERx technology. COL-003 has undergone extensive in vitro dissolution and tamper resistance testing as well as pharmacokinetic
Altrazeal is claimed to be the first wound care dressing to be developed from our nanoparticle aggregate technology. It is an easy to apply and remove powder hydrogel
The agency plans to spend its Prescription Drug User Fee Act (PDUFA IV) fees to fund epidemiology best practices and data acquisition. According to the Drug Safety Five-Year